University of Arizona, Department of Chemistry and Biochemistry , 1306 E. University Blvd., Tucson, AZ 85721 , USA
Expert Opin Drug Discov. 2011 May;6(5):543-57. doi: 10.1517/17460441.2011.565743. Epub 2011 Mar 24.
When establishing the physiological roles of specific receptors in normal and disease states, it is critical to have selective antagonist ligands for each receptor in a receptor system with several subtypes. The melanocortin receptors have five subtypes referred to as the melanocortin 1 receptor, melanocortin 2 receptor, melanocortin 3 receptor, melanocortin 4 receptor and melanocortin 5 receptor, and they are of critical importance for many aspects of human health and disease.
This article reviews the current efforts to design selective antagonistic ligands for the five human melanocortin receptors summarizing the currently published orthosteric and allosteric antagonists for each of these receptors.
Though there has been progress, there are still few drugs available that address the many significant biological activities and diseases that are associated with these receptors, which is possibly due to the lack of receptor selectivity that these designed ligands are currently showing. The authors believe that further studies into the antagonists' 3D conformational and topographical properties in addition to future mutagenesis studies will provide greater insight into these ligands which could play a role in the treatment of various diseases in the future.
在确定特定受体在正常和疾病状态下的生理作用时,对于受体系统中具有几种亚型的每个受体,拥有选择性拮抗剂配体至关重要。黑素皮质素受体有五种亚型,分别称为黑素皮质素 1 受体、黑素皮质素 2 受体、黑素皮质素 3 受体、黑素皮质素 4 受体和黑素皮质素 5 受体,它们对人类健康和疾病的许多方面都至关重要。
本文综述了目前为设计五种人类黑素皮质素受体的选择性拮抗配体所做的努力,总结了目前发表的这些受体的每个受体的正位和变构拮抗剂。
尽管已经取得了一些进展,但仍有很少的药物可用于解决与这些受体相关的许多重要的生物学活性和疾病,这可能是由于这些设计的配体目前显示出的受体选择性缺乏。作者认为,对拮抗剂的 3D 构象和拓扑特性的进一步研究以及未来的突变研究将提供对这些配体的更深入了解,这些配体将来可能在治疗各种疾病中发挥作用。